CHOSA — Chosa Oncology AB Income Statement
0.000.00%
Last trade - 00:00- SEK51.25m
- SEK44.81m
- SEK0.04m
Annual income statement for Chosa Oncology AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | Interim Report | ARS | PRESS |
| Standards: | SAS | SAS | — | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.01 | 10.2 | 4.08 | 0.073 | 0.044 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 53.5 | 72 | 45.4 | 23.6 | 9.76 |
| Operating Profit | -47.5 | -61.9 | -41.3 | -23.5 | -9.71 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -47.9 | -62.1 | -41.3 | -23.8 | -9.59 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -40.2 | -54.6 | -33.4 | -23.9 | -9.59 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -40.2 | -54.6 | -33.4 | -23.9 | -9.59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -40.2 | -54.6 | -33.4 | -23.9 | -9.59 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.11 | -2.87 | -1.75 | -0.37 | -0.14 |
| Dividends per Share |